Antiviral Activity of Technologically Processed Antibodies to CD4 Receptor against Influenza Infection.

Autor: Petrova NV; Research Institute of General Pathology and Pathophysiology, Moscow, Russia. nataliyaapetrova89@gmail.com.; LLC 'MATERIA MEDICA HOLDING', Moscow, Russia. nataliyaapetrova89@gmail.com., Emelyanova AG; Research Institute of General Pathology and Pathophysiology, Moscow, Russia.; LLC 'MATERIA MEDICA HOLDING', Moscow, Russia., Tarasov SA; Research Institute of General Pathology and Pathophysiology, Moscow, Russia.; LLC 'MATERIA MEDICA HOLDING', Moscow, Russia., Glubokova ЕА; I. I. Mechnikov Research Institute of Vaccines and Sera, Moscow, Russia., Каrtashova NP; I. I. Mechnikov Research Institute of Vaccines and Sera, Moscow, Russia.
Jazyk: angličtina
Zdroj: Bulletin of experimental biology and medicine [Bull Exp Biol Med] 2022 Dec; Vol. 174 (2), pp. 250-253. Date of Electronic Publication: 2023 Jan 05.
DOI: 10.1007/s10517-023-05683-8
Abstrakt: The antiviral activity of technologically processed antibodies to CD4 receptor was evaluated a model of sublethal A/California/04/2009 (H1N1)pdm09-induced influenza infection in female BALB/c mice. The technologically processed antibodies increased animal survival rate by 50% in comparison with the placebo group (p<0.05), which correlated with significant inhibition of virus replication in the lungs (p<0.05). The reference drug Tamiflu increased mouse survival rate (by 47%), decreased the virus titer in the lungs, and prevented body weight loss (p<0.05 in comparison with the placebo group by all parameters). The intrinsic protective activity of technologically processed antibodies to CD4 receptor was demonstrated, which manifested in a decrease in viral load in the lower respiratory tract and an increase in the survival rate.
(© 2023. Springer Science+Business Media, LLC, part of Springer Nature.)
Databáze: MEDLINE
Externí odkaz: